Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. | EBSCOhost

Connecting you to content on EBSCOhost

Title: Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Authors: AKIFUMI KUWANO; MASAYOSHI YADA; KOSUKE TANAKA; YUTA KOGA; SHIGEHIRO NAGASAWA; AKIHIDE MASUMOTO; KENTA MOTOMURA
Publication: Cancer Diagnosis & Prognosis, 2024, Vol 4, Issue 1, p34
ISSN: 2732-7787
Publication type: Academic Journal
DOI: 10.21873/cdp.10282